Stock Track | Celcuity Inc Plummets 6.45% on Disappointing Earnings and Clinical Trial Uncertainties

Stock Track2024-11-15

Celcuity Inc (NASDAQ: CELC) saw its stock price plummet by 6.45% in intraday trading on Friday, following the release of its third-quarter 2024 earnings results. The biotechnology company reported a net loss of $29.8 million, wider than the $18.4 million loss in the same period last year.

While the company achieved a significant milestone by fully enrolling patients in the P3CA wild-type cohort for its Victoria 1 phase three clinical trial, concerns arose over the increased expenses and uncertainties surrounding the event rates in its clinical trials.

Research and development expenses soared by $10.1 million compared to the previous year, contributing to the overall financial challenges. Additionally, general and administrative expenses rose to $2.5 million, up from $1.4 million in the third quarter of 2023, reflecting higher operational costs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1131902321?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2024-11-15 22:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131902321","market":"us","top_or_hot":-1,"title":"Stock Track | Celcuity Inc Plummets 6.45% on Disappointing Earnings and Clinical Trial Uncertainties","media":"Stock Track","content":"<p>Celcuity Inc (NASDAQ: CELC) saw its stock price plummet by 6.45% in intraday trading on Friday, following the release of its third-quarter 2024 earnings results. The biotechnology company reported a net loss of $29.8 million, wider than the $18.4 million loss in the same period last year.</p>\n\n<p>While the company achieved a significant milestone by fully enrolling patients in the P3CA wild-type cohort for its Victoria 1 phase three clinical trial, concerns arose over the increased expenses and uncertainties surrounding the event rates in its clinical trials.</p>\n\n<p>Research and development expenses soared by $10.1 million compared to the previous year, contributing to the overall financial challenges. Additionally, general and administrative expenses rose to $2.5 million, up from $1.4 million in the third quarter of 2023, reflecting higher operational costs.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Celcuity Inc Plummets 6.45% on Disappointing Earnings and Clinical Trial Uncertainties</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Celcuity Inc Plummets 6.45% on Disappointing Earnings and Clinical Trial Uncertainties\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-15 22:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Celcuity Inc (NASDAQ: CELC) saw its stock price plummet by 6.45% in intraday trading on Friday, following the release of its third-quarter 2024 earnings results. The biotechnology company reported a net loss of $29.8 million, wider than the $18.4 million loss in the same period last year.</p>\n\n<p>While the company achieved a significant milestone by fully enrolling patients in the P3CA wild-type cohort for its Victoria 1 phase three clinical trial, concerns arose over the increased expenses and uncertainties surrounding the event rates in its clinical trials.</p>\n\n<p>Research and development expenses soared by $10.1 million compared to the previous year, contributing to the overall financial challenges. Additionally, general and administrative expenses rose to $2.5 million, up from $1.4 million in the third quarter of 2023, reflecting higher operational costs.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CELC","symbol_name":"Celcuity Inc","start_time":0,"source_url":"","article_id":"1131902321","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131902321","pubTimestamp":1731681402,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Celcuity Inc  saw its stock price plummet by 6.45% in intraday trading on Friday, following the release of its third-quarter 2024 earnings results. The biotechnology company reported a net loss of $29.8 million, wider than the $18.4 million loss in the same period last year.While the company achieved a significant milestone by fully enrolling patients in the P3CA wild-type cohort for its Victoria 1 phase three clinical trial, concerns arose over the increased expenses and uncertainties surroundi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CELC":"Celcuity Inc"},"translate_title":"股票跟踪Celcuity Inc因盈利令人失望和临床试验不确定性而暴跌6.45%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CELC":1},"content_text":"Celcuity Inc (NASDAQ: CELC) saw its stock price plummet by 6.45% in intraday trading on Friday, following the release of its third-quarter 2024 earnings results. The biotechnology company reported a net loss of $29.8 million, wider than the $18.4 million loss in the same period last year.\nWhile the company achieved a significant milestone by fully enrolling patients in the P3CA wild-type cohort for its Victoria 1 phase three clinical trial, concerns arose over the increased expenses and uncertainties surrounding the event rates in its clinical trials.\nResearch and development expenses soared by $10.1 million compared to the previous year, contributing to the overall financial challenges. Additionally, general and administrative expenses rose to $2.5 million, up from $1.4 million in the third quarter of 2023, reflecting higher operational costs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1131902321"}